Beyond Air (NASDAQ:XAIR) Issues Earnings Results, Misses Expectations By $0.45 EPS

Beyond Air (NASDAQ:XAIR) issued its quarterly earnings data on Wednesday. The company reported ($3.76) EPS for the quarter, missing analysts’ consensus estimates of ($3.31) by ($0.45), Zacks reports. Beyond Air had a negative net margin of 435.71% and a negative return on equity of 440.26%. The business had revenue of $2.32 million during the quarter, compared to analyst estimates of $2.16 million.

Here are the key takeaways from Beyond Air’s conference call:

• Beyond Air reported record quarterly revenue of $2.3 million, up 28% year over year and 31% from the June quarter; gross margin improved to 8% from negative 16% a year earlier.
• The second-generation LungFit PH remains under FDA review. The company expects to complete audit readiness by mid-December, but inspection and final approval timing remain subject to the FDA.
• Management reaffirmed calendar 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million. The 2027 forecast assumes second-generation system revenue in the second through fourth quarters, pending FDA approval.
• Management said the U.S. commercial pipeline has more than doubled since it was cleaned up and is converting into new customer wins; it also cited growing renewals and strong international sales.
• The company reported a $7.8 million quarterly net loss attributable to common stockholders and $18.5 million in cash, restricted cash, and marketable securities, including funds held by subsidiaries and $4.8 million of restricted cash.

Beyond Air Price Performance

Shares of XAIR opened at $2.63 on Thursday. Beyond Air has a fifty-two week low of $2.05 and a fifty-two week high of $53.20. The stock has a fifty day moving average of $2.66 and a two-hundred day moving average of $9.40. The company has a current ratio of 3.31, a quick ratio of 3.12 and a debt-to-equity ratio of 7.81.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on XAIR shares. Weiss Ratings raised shares of Beyond Air from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. Lake Street Capital assumed coverage on shares of Beyond Air in a research note on Tuesday, September 1st. They set a “buy” rating and a $10.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $105.00.

About Beyond Air

Beyond Air, Inc. is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders. The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings. LungFit PH is designed to deliver inhaled nitric oxide to term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.